Balancing novelty with confined chemical space in modern drug discovery

Introduction: The concept of chemical space has broad applications in drug discovery. In response to the needs of drug discovery campaigns, different approaches are followed to efficiently populate, mine and select relevant chemical spaces that overlap with biologically relevant chemical spaces. Areas covered: This paper reviews major trends in current drug discovery and their impact on the mining and population of chemical space. We also survey different approaches to develop screening libraries with confined chemical spaces balancing physicochemical properties. In this context, the confinement is guided by criteria that can be divided in two broad categories: i) library design focused on a relevant therapeutic target or disease and ii) library design focused on the chemistry or a desired molecular function. Expert opinion: The design and development of chemical libraries should be associated with the specific purpose of the library and the project goals. The high complexity of drug discovery and the inherent imperfection of individual experimental and computational technologies prompt the integration of complementary library design and screening approaches to expedite the identification of new and better drugs. Library design approaches including diversity-oriented synthesis, biological-oriented synthesis or combinatorial library design, to name a few, and the design of focused libraries driven by target/disease, chemical structure or molecular function are more efficient if they are guided by multi-parameter optimization. In this context, consideration of pharmaceutically relevant properties is essential for balancing novelty with chemical space in drug discovery.

[1]  Bryan L. Roth,et al.  Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.

[2]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[3]  Matteo Floris,et al.  Swimming into peptidomimetic chemical space using pepMMsMIMIC , 2011, Nucleic Acids Res..

[4]  José L. Medina-Franco,et al.  Chemoinformatic Analysis of GRAS (Generally Recognized as Safe) Flavor Chemicals and Natural Products , 2012, PloS one.

[5]  Simona Bohanec,et al.  Structure generation of constitutional isomers from structural fragments , 1991, J. Chem. Inf. Comput. Sci..

[6]  Dik-Lung Ma,et al.  Drug repositioning by structure-based virtual screening. , 2013, Chemical Society reviews.

[7]  José L Medina-Franco,et al.  Design and synthesis of α‐conotoxin GID analogues as selective α4β2 nicotinic acetylcholine receptor antagonists , 2014, Biopolymers.

[8]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[9]  Michele Saviano,et al.  Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystokinin Type B Receptor , 2006, ChemMedChem.

[10]  Peter Ertl,et al.  The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.

[11]  Francesco Marchetti,et al.  Towards the Systematic Exploration of Chemical Space , 2012 .

[12]  Philippe Roche,et al.  2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions , 2012, Nucleic Acids Res..

[13]  Michael Entzeroth,et al.  Focused Libraries: The Evolution in Strategy from Large-Diversity Libraries to the Focused Library Approach , 2006 .

[14]  Alicia P. Higueruelo,et al.  Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database , 2009, Chemical biology & drug design.

[15]  Thorsten Nowak,et al.  Expanding medicinal chemistry space. , 2013, Drug discovery today.

[16]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[17]  P. Wipf,et al.  Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. , 2013, Journal of the American Chemical Society.

[18]  D. H. Williams,et al.  Iminosugars past, present and future: medicines for tomorrow. , 2011, Drug discovery today.

[19]  A. Ganesan The impact of natural products upon modern drug discovery. , 2008, Current opinion in chemical biology.

[20]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[21]  J. Medina-Franco,et al.  Systematic mining of generally recognized as safe (GRAS) flavor chemicals for bioactive compounds. , 2013, Journal of agricultural and food chemistry.

[22]  M. Carmen Galan,et al.  Carbohydrate Chemistry in Drug Discovery , 2011 .

[23]  Deepak Bandyopadhyay,et al.  Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes , 2012, Journal of biomolecular screening.

[24]  Rachelle J Bienstock,et al.  Computational drug design targeting protein-protein interactions. , 2012, Current pharmaceutical design.

[25]  L. Cipolla,et al.  Carbohydrate-based bioactive compounds for medicinal chemistry applications. , 2011, Mini reviews in medicinal chemistry.

[26]  Ian H Gilbert,et al.  Finding new hits in neglected disease projects: target or phenotypic based screening? , 2011, Current topics in medicinal chemistry.

[27]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[28]  Jean-Louis Reymond,et al.  Visualization and Virtual Screening of the Chemical Universe Database GDB-17 , 2013, J. Chem. Inf. Model..

[29]  Alberto Del Rio,et al.  Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives , 2012, Current pharmaceutical design.

[30]  Michal Sabat,et al.  Diversity Space and Its Application to Library Selection and Design , 2006, J. Chem. Inf. Model..

[31]  Bruno Giethlen,et al.  Chapter 15 – Molecular Variations Based on Isosteric Replacements , 2008 .

[32]  J. Medina-Franco,et al.  Inhibitors of DNA methyltransferases: insights from computational studies. , 2012, Current medicinal chemistry.

[33]  J. Medina-Franco,et al.  The prince and the pauper. A tale of anticancer targeted agents , 2008, Molecular Cancer.

[34]  Jürgen Bajorath,et al.  A Perspective on Computational Chemogenomics , 2013, Molecular informatics.

[35]  Jeffrey Aubé,et al.  Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.

[36]  Craig W Lindsley,et al.  Application of combinatorial chemistry science on modern drug discovery. , 2008, Journal of combinatorial chemistry.

[37]  Ingo Muegge Synergies of virtual screening approaches. , 2008, Mini reviews in medicinal chemistry.

[38]  Julian Tirado-Rives,et al.  Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of Plasmodium falciparum macrophage migration inhibitory factor. , 2012, Journal of medicinal chemistry.

[39]  Stuart L. Schreiber,et al.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.

[40]  Alberto Del Rio,et al.  Freely accessible databases of commercial compounds for high- throughput virtual screenings. , 2012, Current topics in medicinal chemistry.

[41]  José L. Medina-Franco,et al.  A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions , 2013, Journal of Cell Science.

[42]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[43]  D. E. Clark What has virtual screening ever done for drug discovery? , 2008, Expert opinion on drug discovery.

[44]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[45]  José L Medina-Franco,et al.  Molecular Scaffold Analysis of Natural Products Databases in the Public Domain , 2012, Chemical biology & drug design.

[46]  Stephen R. Johnson,et al.  Chapter 9:Compound Library Design – Principles and Applications , 2008 .

[47]  José L. Medina-Franco,et al.  ADVANCES IN COMPUTATIONAL APPROACHES FOR DRUG DISCOVERY BASED ON NATURAL PRODUCTS , 2013 .

[48]  G. Verdine,et al.  Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.

[49]  Richard A. Houghten,et al.  Combinatorial Chemistry: Libraries from Libraries, the Art of the Diversity‐Oriented Transformation of Resin‐Bound Peptides and Chiral Polyamides to Low Molecular Weight Acyclic and Heterocyclic Compounds , 2004 .

[50]  José L. Medina-Franco,et al.  Data Mining of Protein-Binding Profiling Data Identifies Structural Modifications that Distinguish Selective and Promiscuous Compounds , 2012, J. Chem. Inf. Model..

[51]  Sivaraman Dandapani,et al.  Grand challenge commentary: Accessing new chemical space for 'undruggable' targets. , 2010, Nature chemical biology.

[52]  Valery M. Dembitsky,et al.  Anticancer activity of natural and synthetic acetylenic lipids , 2006, Lipids.

[53]  Yoo Jakyung,et al.  Chemoinformatic Approaches for Inhibitors of DNA Methyltransferases: Comprehensive Characterization of Screening Libraries , 2011 .

[54]  David B Jackson,et al.  Drug profiling: knowing where it hits. , 2010, Drug discovery today.

[55]  Nathan Brown,et al.  On scaffolds and hopping in medicinal chemistry. , 2006, Mini reviews in medicinal chemistry.

[56]  Paul A Clemons,et al.  Complex phenotypic assays in high-throughput screening. , 2004, Current opinion in chemical biology.

[57]  Stephen D. Roughley,et al.  The Medicinal Chemist′s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates , 2011 .

[58]  Gilles Gasser,et al.  The potential of organometallic complexes in medicinal chemistry. , 2012, Current opinion in chemical biology.

[59]  Clemencia Pinilla,et al.  Integrating computational and mixture-based screening of combinatorial libraries , 2011, Journal of molecular modeling.

[60]  Philippe Vayer,et al.  Toward in silico structure-based ADMET prediction in drug discovery. , 2012, Drug discovery today.

[61]  Jaime Pérez-Villanueva,et al.  Chemoinformatic characterization of activity and selectivity switches of antiprotozoal compounds. , 2014, Future medicinal chemistry.

[62]  David J Craik,et al.  Therapeutic potential of conopeptides. , 2012, Future medicinal chemistry.

[63]  Sarah R. Langdon,et al.  Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..

[64]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[65]  F Ivy Carroll,et al.  From rapid In Vitro screening to rapid In Vivo screening in the drug discovery process , 2009, Neuropsychopharmacology.

[66]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[67]  Michael D Shultz,et al.  Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters. , 2013, Bioorganic & medicinal chemistry letters.

[68]  Jürgen Bajorath,et al.  Mapping of pharmacological space , 2011, Expert opinion on drug discovery.

[69]  Giovanna Zinzalla,et al.  Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. , 2009, Future medicinal chemistry.

[70]  W. Pitt,et al.  Heteroaromatic rings of the future. , 2009, Journal of medicinal chemistry.

[71]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[72]  D Rognan,et al.  Towards the Next Generation of Computational Chemogenomics Tools , 2013, Molecular informatics.

[73]  Andrea Trabocchi,et al.  Diversity-Oriented Synthesis: Basics and Applications in Organic Synthesis, Drug Discovery, and Chemical Biology , 2013 .

[74]  Bruno Giethlen,et al.  Molecular Variations Based on Isosteric Replacements , 2008 .

[75]  Karina Martinez-Mayorga,et al.  Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure. , 2013, European journal of medicinal chemistry.

[76]  José L. Medina-Franco,et al.  Chemoinformatic Characterization of the Chemical Space and Molecular Diversity of Compound Libraries , 2013 .

[77]  Hong-Yu Zhang,et al.  Exploring the Biologically Relevant Chemical Space for Drug Discovery , 2013, J. Chem. Inf. Model..

[78]  J. Reichert,et al.  Future directions for peptide therapeutics development. , 2013, Drug discovery today.

[79]  M. Hann,et al.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.

[80]  Paul Ernsberger,et al.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Clemencia Pinilla,et al.  Rapid Scanning Structure-Activity Relationships in Combinatorial Data Sets: Identification of Activity Switches , 2013, J. Chem. Inf. Model..

[82]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[83]  Peter Ertl,et al.  Evolution of the physicochemical properties of marketed drugs: can history foretell the future? , 2011, Drug discovery today.

[84]  J. Medina-Franco,et al.  Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.

[85]  Iskander Yusof,et al.  Considering the impact drug-like properties have on the chance of success. , 2013, Drug discovery today.

[86]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[87]  Austin B. Yongye,et al.  Modeling of peptides containing D-amino acids: implications on cyclization , 2009, J. Comput. Aided Mol. Des..

[88]  Markus Hartenfeller,et al.  DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..

[89]  Eric Meggers,et al.  Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.

[90]  Pasi Soininen,et al.  Activity and stability of human kallikrein‐2‐specific linear and cyclic peptide inhibitors , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[91]  C. Heinis,et al.  Polycyclic Peptide Therapeutics , 2013 .

[92]  José L. Medina-Franco,et al.  Increased Diversity of Libraries from Libraries: Chemoinformatic Analysis of Bis‐Diazacyclic Libraries , 2011, Chemical biology & drug design.

[93]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[94]  Matthew D Segall,et al.  Multi-parameter optimization: identifying high quality compounds with a balance of properties. , 2012, Current pharmaceutical design.

[95]  Rajarshi Guha,et al.  Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..

[96]  Clemencia Pinilla,et al.  Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. , 2008, Journal of combinatorial chemistry.

[97]  José L. Medina-Franco,et al.  Visualization of the Chemical Space in Drug Discovery , 2008 .

[98]  Scott Boyer,et al.  A critical assessment of modeling safety-related drug attrition , 2013 .

[99]  José L Medina-Franco,et al.  Progress in the Visualization and Mining of Chemical and Target Spaces , 2013, Molecular informatics.

[100]  José L. Medina-Franco,et al.  Scaffold Diversity Analysis of Compound Data Sets Using an Entropy-Based Measure , 2009 .

[101]  M Berrie Division of chemical information. , 2000, IDrugs : the investigational drugs journal.

[102]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[103]  Fabian López-Vallejo,et al.  Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. , 2011, Combinatorial chemistry & high throughput screening.

[104]  Bryan L. Roth,et al.  Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Ian Collins,et al.  Macrocycles in new drug discovery. , 2012, Future medicinal chemistry.

[106]  K. M. Smith,et al.  Novel software tools for chemical diversity , 1998 .

[107]  Sébastien Granier,et al.  A new era of GPCR structural and chemical biology. , 2012, Nature chemical biology.

[108]  Fabrizio Giordanetto,et al.  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.

[109]  Landon R. Whitby,et al.  Comprehensive peptidomimetic libraries targeting protein-protein interactions. , 2012, Accounts of chemical research.

[110]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[111]  C. Franceschi,et al.  Immunoproteasome in cancer and neuropathologies: a new therapeutic target? , 2012, Current pharmaceutical design.

[112]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[113]  Harshil Dhruv,et al.  Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis* , 2013, The Journal of Biological Chemistry.

[114]  Hiroshi Murakami,et al.  Ribosomal synthesis of bicyclic peptides via two orthogonal inter-side-chain reactions. , 2008, Journal of the American Chemical Society.

[115]  J. Bajorath,et al.  Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening. , 2010, Journal of medicinal chemistry.

[116]  José L Medina-Franco,et al.  Systematic characterization of structure-activity relationships and ADMET compliance: a case study. , 2013, Drug discovery today.

[117]  J. Medina-Franco,et al.  Expanding the medicinally relevant chemical space with compound libraries. , 2012, Drug discovery today.

[118]  Alfredo Ortega,et al.  Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae) , 1982 .

[119]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.